The conversation is about choosing an anti-androgen for hair loss treatment, with options being alfatradiol and pyrilutamide. Alfatradiol is considered a better choice due to its established use, while pyrilutamide is more experimental.
A 27-year-old using minoxidil and dutasteride for hair loss has seen significant improvement but is considering a hair transplant for a more defined hairline. Most responses suggest the hair looks good, advise against a transplant, and recommend patience or trying microneedling or tretinoin.
A private clinic suggests starting with topical Minoxidil only, raising concerns about DHT blocking and potential side effects of Finasteride. The user is considering whether to follow this plan or use a combination of Minoxidil and Finasteride for hair thinning.
The conversation discusses hair loss treatments, focusing on the use of finasteride and minoxidil. It suggests starting with finasteride alone to assess its effectiveness before adding other treatments like minoxidil, while noting that biotin and caffeine shampoo are unlikely to help unless there's a deficiency.
The conversation is a humorous take on someone's reaction after their first dose of finasteride for hair loss. Specific treatments mentioned include scalp massage and a protocol of manifestation twice daily.
The conversation discusses hair loss and queries the effectiveness of treatments like PRP, Exosome therapy, peptides, and Stem Cell therapy. Specific treatments like Minoxidil, finasteride, and RU58841 are also mentioned.
The conversation lists hair loss treatments including finasteride, dutasteride, RU58841, pyrilutamide, breezula, and fluridil, and suggests ketoconazole as another option. Some users warn against using certain treatments like cyproterone acetate, bicalutamide, and spironolactone due to their strong anti-androgen effects and potential impact on masculinity.
PP405 is a promising new treatment for hair loss that activates dormant stem cells in hair follicles, potentially bypassing the effects of DHT. It is currently in phase 2 trials and could be available between 2027 and 2030, but it is not considered a definitive cure.